Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
IPO Year:
Exchange: NYSE
Website: abbott.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/30/2024 | Buy → Hold | Edward Jones | |
5/30/2024 | $121.00 | Buy | Goldman |
7/21/2023 | Underperform → Peer Perform | Wolfe Research | |
5/30/2023 | $112.00 | Overweight → Equal-Weight | Morgan Stanley |
4/20/2023 | $125.00 → $127.00 | Overweight | Barclays |
4/20/2023 | $107.00 → $103.00 | Underperform | Wolfe Research |
4/20/2023 | $132.00 → $133.00 | Outperform | Bernstein |
4/20/2023 | $118.00 → $122.00 | Overweight | JP Morgan |
4/20/2023 | $116.00 → $123.00 | Outperform | Raymond James |
4/20/2023 | $117.00 → $130.00 | Buy | UBS |
Designed for people interested in improving their overall health and wellnessProvides real-time glucose data and personal coaching insights based on the body's reaction to nutrition, exercise and life's daily stressorsAvailable without a prescription; explore different purchase options at www.hellolingo.com ABBOTT PARK, Ill., Sept. 5, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced U.S. availability of Lingo™, the company's first continuous glucose monitoring system available without a prescription. The Lingo system includes a biosensor and a mobile app designed for consumers who want to improve their overall health and wellness. Lingo is based on Abbott's world-leading FreeStyle Lib
The U.S. FDA granted Abbott Breakthrough Device designation to explore deep brain stimulation (DBS) for treatment-resistant depression (TRD) as an option to improve the lives of people with this debilitating conditionApproximately 2.8 million Americans each year are diagnosed with TRD, a form of major depressive disorder that has not responded to two or more treatments1 ABBOTT PARK, Ill., Sept. 4, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) announced today it has initiated a pivotal clinical trial, called the TRANSCEND study, to evaluate the use of the company's deep brain stimulation (DBS) system to manage treatment-resistant depression (TRD), a form of major depressive disorder. The U.S. Food a
Pure Bliss™ Organic and Pure Bliss Organic with A2 Milk infant formulas – both USDA-certified – are now part of the Pure Bliss by Similac® line that includes European-made Pure Bliss Irish Farms, which starts with fresh milk from cows in IrelandPure Bliss Organic in the 2-fluid ounce ready-to-feed bottle is the only USDA-certified organic liquid infant formula offered in select U.S. retail storesPure Bliss by Similac delivers a selection of organic or European-made infant formulas that provide gentle, complete nutrition and specifically sourced ingredientsABBOTT PARK, Ill., Aug. 27, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced the expansion of its Pure Bliss™ by Similac® line of or
Abbott's AVEIR™ DR leadless pacemaker system was first implanted at the Montreal Heart Institute in Montreal, Quebec and Foothills Medical Centre in Calgary, AlbertaThe AVEIR DR leadless pacemaker system is designed to address abnormal heart rhythms 1Abbott's first-of-its-kind i2i™ technology enables synchronized communication between two leadless pacemakers, which are each roughly one-tenth the size of a traditional pacemaker1MONTREAL, Aug. 15, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the AVEIR™ dual chamber (DR) leadless pacemaker system, the world's first dual chamber leadless pacemaker system that treats people with abnormal or slow heart rhythms,1 has been implanted for the
MISSISSAUGA, ON, Aug. 8, 2024 /CNW/ -- Abbott (NYSE:ABT) today announced that the Government of Quebec's Régie de l'assurance maladie du Québec (RAMQ) published an update to its formulary that includes expanded reimbursement for Abbott's FreeStyle Libre 2* flash glucose monitoring system to more adults living with type 1 and type 2 diabetes. As of July 4, 2024, provincial reimbursement criteria expanded for individuals 18 years of age and older with type 1 or type 2 diabetes who are treated with intensive insulin to include those who also meet one or more of the following criteria: Those who have not been able to achieve their targeted hemoglobin A1c (HbA1c) or who are unable to recognize
PONTE VEDRA, Fla., Aug. 6, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc., (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a late-stage, new-generation Vitamin K Antagonist (VKA) oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices and those with rare cardiovascular conditions, announced today that it has been in discussions with Abbott (NYSE:ABT) about Cadrenal's planned pivotal study of tecarfarin in patients with recently implanted LVADs. All patients with LVADs require lifelong anticoagulation (AC) to protect against thromboembolic events.
Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with new product approvalsABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024. Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items.Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS
ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica
Eight health centers across the U.S. participate in Innovation Incubator to find new ways to integrate healthy food into clinical careNow in its second year, the goal of the Innovation Incubator is to share what works with 1,400 health centers providing affordable care for 31+ millionABBOTT PARK, Ill. and BETHESDA, Md., June 20, 2024 /PRNewswire/ -- The global healthcare company Abbott (NYSE:ABT) and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative. Eight community health centers have been selected to receive funding, expert guidance and training to design and t
ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 402nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2024, to shareholders of record at the close of business on July 15, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
For Immediate Release: October 24, 2023 Today, the U.S. Food and Drug Administration approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. This is the first targeted therapy approved for this indication. The agency also approved the Abbott RealTime
10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
11-K - ABBOTT LABORATORIES (0000001800) (Filer)
SD - ABBOTT LABORATORIES (0000001800) (Filer)
10-Q - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
8-K - ABBOTT LABORATORIES (0000001800) (Filer)
ARS - ABBOTT LABORATORIES (0000001800) (Filer)
DEF 14A - ABBOTT LABORATORIES (0000001800) (Filer)
Sales of $10.4 billion driven by strong underlying base business performance Reported sales growth of 4.0 percent; organic sales growth for underlying base business of 9.3 percent1, led by double-digit growth in Medical DevicesContinues to strengthen portfolio with new product approvalsABBOTT PARK, Ill., July 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2024. Second-quarter GAAP diluted EPS of $0.74 and adjusted diluted EPS of $1.14, which excludes specified items.Abbott raised its full-year 2024 EPS guidance range. Abbott projects full-year diluted EPS on a GAAP basis of $3.30 to $3.40 and projects adjusted diluted EPS
ABBOTT PARK, Ill., June 27, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its second-quarter 2024 financial results on Thursday, July 18, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica
ABBOTT PARK, Ill., June 14, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE:ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 402nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2024, to shareholders of record at the close of business on July 15, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio
Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) today announced financial results for the first quarter ended March 31, 2024. First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified items.Abbott narrowed its full-year 2024 EPS guidance range. Abbott projects full-year diluted
ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share. This marks the 401st consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable May 15, 2024, to shareholders of record at the close of business on April 15, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends annually for at least 25 consecutive years. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfoli
Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percentFull-year 2023 reported sales decreased 8.1 percent due to anticipated decline in COVID-19 testing-related sales; organic sales growth for the underlying base business increased 11.6 percentFull-year 2023 GAAP diluted EPS of $3.26; adjusted diluted EPS of $4.44R&D pipeline continues to deliver steady cadence of new productsABBOTT PARK, Ill., Jan. 24, 2024 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2023. Fourth-quarter sales increased 1.5 percent on a reported basis, 2.1 percent on an organic basis, and 11.0 perce
ABBOTT PARK, Ill., Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medica
Dividend increased by 7.8%400th consecutive quarterly dividend to be paid by Abbott since 1924Company continues to deliver strong shareholder returns and top-tier growthABBOTT PARK, Ill., Dec. 15, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) today announced that its board of directors has increased the company's quarterly common dividend to 55 cents per share, an increase of 7.8%. This marks the company's 52nd consecutive year of dividend growth. It will be the 400th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Feb. 15, 2024, to shareholders of record at the close of business on Jan. 12, 2024. Abbott is a member of the S&P 500 Dividend Aristocrats I
ABBOTT PARK, Ill., Sept. 27, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens. The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available later that day. About Abbott:Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medic
ABBOTT PARK, Ill., Sept. 22, 2023 /PRNewswire/ -- Abbott (NYSE:ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes. The transaction expands Abbott's presence in diabetes care, building on its world-leading FreeStyle Libre® portfolio of continuous glucose monitoring technology and furthering the company's efforts to develop connected solutions for making diabetes management even more personal and precise. Pursuant to the terms of the merger agreement, upon completion of the acquisition, Bigfoot became a wholly owned subsidiary of Abbott. Financial terms were not disclosed. About AbbottAb
Edward Jones downgraded Abbott Labs from Buy to Hold
Goldman initiated coverage of Abbott Labs with a rating of Buy and set a new price target of $121.00
Wolfe Research upgraded Abbott Labs from Underperform to Peer Perform
Morgan Stanley downgraded Abbott Labs from Overweight to Equal-Weight and set a new price target of $112.00
Barclays reiterated coverage of Abbott Labs with a rating of Overweight and set a new price target of $127.00 from $125.00 previously
Wolfe Research reiterated coverage of Abbott Labs with a rating of Underperform and set a new price target of $103.00 from $107.00 previously
Bernstein reiterated coverage of Abbott Labs with a rating of Outperform and set a new price target of $133.00 from $132.00 previously
JP Morgan reiterated coverage of Abbott Labs with a rating of Overweight and set a new price target of $122.00 from $118.00 previously
Raymond James reiterated coverage of Abbott Labs with a rating of Outperform and set a new price target of $123.00 from $116.00 previously
UBS reiterated coverage of Abbott Labs with a rating of Buy and set a new price target of $130.00 from $117.00 previously
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
SC 13G/A - ABBOTT LABORATORIES (0000001800) (Subject)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
4 - ABBOTT LABORATORIES (0000001800) (Issuer)
PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the appointment of Catherine Mazzacco to its Board of Directors. "I am pleased to welcome Catherine to our Board of Directors at this crucial next stage of Krystal's evolution," said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech, Inc. "As a seasoned executive with extensive valuable pharmaceutical and biotechnology industry experience, I look forward to Catherine's involvement and assistance in guiding our strategic objectives." "A
Westport, CT, March 16, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ:BSGM) ("BioSig" or the "Company"), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced the appointment of John Sieckhaus as Chief Operating Officer. Mr. Sieckhaus brings to the Company 30 years in the healthcare industry, including 21 years at St. Jude Medical and Abbott Laboratories (NYSE:ABT). During his tenure with St. Jude Medical, Mr. Sieckhaus held commercial leadership positions of rising responsibility, including U.S. National Sales Leader, Senior Vice P
LOS ANGELES, Jan. 11, 2022 /PRNewswire/ -- ACELYRIN, INC., a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates, today announced the appointment of Melanie Gloria, BSN, as the company's chief operating officer (COO). In this role, Ms. Gloria will oversee business operations across the company. A former oncology nurse, Ms. Gloria has two decades' experience in the biotechnology industry having led a variety of research and development (R&D
NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le
ABBOTT PARK, Ill., Dec. 10, 2021 /PRNewswire/ -- Abbott (NYSE:ABT) announced that its Board of Directors has elected Chief Executive Officer Robert B. Ford as Chairman of the Board, effective today. Miles D. White, executive chairman and former CEO, will step down from the Abbott Board effective today and will retire after a remarkable 38-year career with the Company. "We're grateful for Miles' leadership and his exceptional work to transform Abbott into the leading health technology company that it is today," said William A. Osborn, lead director and chair of the Nominations and Governance committee. "Robert has continued to strengthen Abbott's position by advancing our industry-leading pip
PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, today announced the appointment of Curt Bradshaw, Ph.D., as its new Chief Scientific Officer. Dr. Bradshaw is a proven drug developer in the field of precision genetic medicines, coming to NeuBase from his most recent role as Chief Scientific Officer at Arrowhead Pharmaceuticals. In his new role, Dr. Bradshaw will be responsible for leading and expanding NeuBase’s PATrOL-enabled anti-gene pipeline and will serve as a key member of its executive management team. “
Abbott Laboratories (NYSE:ABT) CEO Robert Ford said the company will use a mix of TV advertisements and guerilla marketing to promote the U.S. launch of Lingo, its glucose monitoring device. This device targets consumers without diabetes, aiming to personalize health data and enhance understanding of their health metrics. Also Read: Similac Baby Formula Maker Abbott And Reckitt Face Hundreds Of Baby Formula Lawsuits. Ford projected that Lingo could become a multi-billion-dollar product, although it is still in its nascent stage. Lingo, an over-the-counter device, is scheduled to launch this year alongside Libre Rio, which received FDA clearance last month. Abbott’s consumer bi
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the “Neutral” zone on Thursday. U.S. stocks closed lower on Thursday, with the Dow Jones index falling more than 500 points during the session. On the economic data front, U.S. initial jobless claims increased by 10,000 to 243,000 in the week ending July 13, compared to market estimates of 230,000. The Philadelphia Fed Manufacturing Index rose to 13.9 in July, recording the strongest level in three months, versus 1.3 in June. Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday. D.R. Horton, Inc. (NYSE:DHI) reported stronge
Shares of Abbott Laboratories (NYSE:ABT) are trading lower on Thursday following the company’s second-quarter 2024 financial results. What’s Going On: Abbott reported second-quarter sales of $10.377 billion, slightly beating the $10.371 billion estimate. EPS came in at $1.14, surpassing analyst estimates of $1.10. The company also saw a 10.2% increase in sales to $4.73 billion and a 12.1% organic growth rate. This growth included double-digit gains in Diabetes Care, Electrophysiology and Structural Heart sectors. Despite the growth in medical devices, diagnostics sales were impacted by a year-over-year decline in COVID-19 testing-related sales, which dropped to $102 million from $26
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday. The Dow traded down 1.08% to 40,752.05 while the NASDAQ fell 0.80% to 17,853.34. The S&P 500 also fell, dropping, 0.75% to 5,546.48. Check This Out: Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July Leading and Lagging SectorsEnergy shares jumped by 1.1% on Thursday. In trading on Thursday, health care shares fell by 1.6%. Top Headline Abbott Laboratories (NYSE:ABT) reported better-than-expected earnings for its second quarter on Thursday. The company posted sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 bil
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels last seen in late April. Both the S&P 500 and the Nasdaq 100 indices declined by 0.6%, while the Dow Jones Industrial Average fell 0.7%, potentially ending a streak of six consecutive positive sessions. Small-cap stocks also succumbed to the broader negative sentiment, with the Russell 2000 index dropping 0.7%. Chicago Fed President Austan Goolsbee, a known “dove” on the board, expressed optimism about progress on inflation and the U.S. economy’s resilience in avoiding a recession. He
On Thursday, Abbott Laboratories (NYSE:ABT) reported second-quarter sales of $10.38 billion, up 4%, almost in line with the consensus of $10.37 billion. Organic sales growth for the underlying base business was 9.3%, led by double-digit growth in Medical Devices. Abbott’s adjusted diluted earnings per share was $1.14, beating the analyst estimates of $1.10. Medical Devices sales increased 10.2% to $4.73 billion and 12.1% organically in the second quarter, including double-digit organic growth in the U.S. and internationally. Sales growth was led by double-digit growth in Diabetes Care, Electrophysiology, and Structural Heart. Year-over-year declines in COVID-19 testing-related sa
Beaten-down stocks could make a comeback on Thursday, with Taiwan Semiconductor Manufacturing Company Ltd.’s (NYSE:TSM) strong quarterly report lifting sentiment toward tech stocks. The major U.S. index futures were mixed ahead of the trading session. A few Fed speeches scheduled for the day, and key economic data, including jobless claims, the results of a regional manufacturing survey, and leading economic index may influence trading direction. Traders may also pay attention to the European Central Bank’s rate decision and its monetary policy outlook. FuturesPerformance (+/-)Nasdaq 100+0.40%S&P 500+0.15%Dow-0.13%R2K-0.03% In premarket trading on Thursday, the SPDR S&P 500 ETF Trus